Literature DB >> 12115163

Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis.

Eva Reinhold-Keller1, Karen Herlyn, Rosemarie Wagner-Bastmeyer, Joachim Gutfleisch, Hartmut H Peter, Heiner H Raspe, Wolfgang L Gross.   

Abstract

OBJECTIVES: To evaluate the effects of Wegener's granulomatosis (WG) on employment status, work disability, and need for medical care of 60 consecutive WG patients aged < or = 40 years at diagnosis.
METHODS: Sixty WG patients (26 male, 34 female) with a median age of 36 years (range 17-48 years) and a median duration of disease of 39 months (range 0-228 months) completed self-administered questionnaires on hospitalization, medical care, and employment status plus the Medical Outcomes Study-Short Form-36 (SF-36) estimating their health-related quality of life.
RESULTS: Thirty-two of the 60 patients reported full- or part-time employment more than 3 years after diagnosis. Only 14 of the 51 patients employed at diagnosis (27%) were currently receiving a permanent work disability pension due to WG. Two additional patients had lost work because of WG. Women who were employed at diagnosis had a nearly 3-fold higher risk of losing their jobs compared with men (P = 0.0006). There were no differences with regard to age at diagnosis, disease duration, disease severity, or education level between employed and unemployed patients. Employed patients had missed a median of 14 workdays (range 0-18 days) due to WG within the past 12 months. More than half of all patients (33 of 60) had been hospitalized during the previous 12 months because of WG. Ninety-three percent of all patients had visited their physician once or more per month, more than half of them at least once per week, regardless of employment status, severity of disease, or type of current medication. Unemployed WG patients experienced significant reductions in social and physical function and in their perceived degree of general health as assessed by the SF-36.
CONCLUSIONS: Twenty-seven percent of WG patients younger than age 40 who were employed at diagnosis received permanent work disability within a disease duration of 39 months. Unemployment is followed by a considerable reduction in disease-related quality of life compared with employed patients, independent of severity and extent of disease. Furthermore, because patients were followed closely by an interdisciplinary team, a high rate of hospitalization and frequent visits to physicians resulted.

Entities:  

Mesh:

Year:  2002        PMID: 12115163     DOI: 10.1002/art.10458

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

2.  Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise.

Authors:  N Milman; A Boonen; P Tugwell; P A Merkel
Journal:  Scand J Rheumatol       Date:  2016-07-20       Impact factor: 3.641

Review 3.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 4.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

5.  The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission.

Authors:  Delesha M Carpenter; Jessica A Kadis; Robert F Devellis; Susan L Hogan; Joanne M Jordan
Journal:  J Rheumatol       Date:  2011-02-01       Impact factor: 4.666

Review 6.  [Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; M Engel; E Genth; B Greitemann; W H Jäckel; A Zink
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

Review 7.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

8.  Health-related quality of life for patients with vasculitis and their spouses.

Authors:  Delesha M Carpenter; Carolyn T Thorpe; Megan Lewis; Robert F Devellis; Susan L Hogan
Journal:  Arthritis Rheum       Date:  2009-02-15

9.  Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients.

Authors:  Servet Akar; Gercek Can; Omer Binicier; Kenan Aksu; Baris Akinci; Dilek Solmaz; Merih Birlik; Gökhan Keser; Nurullah Akkoc; Fatos Onen
Journal:  Clin Rheumatol       Date:  2007-12-21       Impact factor: 2.980

10.  Patient perceptions about illness self-management in ANCA-associated small vessel vasculitis.

Authors:  C T Thorpe; R F DeVellis; S J Blalock; S L Hogan; M A Lewis; B M DeVellis
Journal:  Rheumatology (Oxford)       Date:  2008-04-09       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.